Serum analytes were collected from a total of 651 subjects available in the LCC (Table 1A) with an approximate 2:1 ratio in the number of LRRK2+ subjects to the number of LRRK2− subjects and an approximate 1:2 ratio in the number of PD subjects to the number of non-PD subjects. This evidence concerns the gene LRRK2 and Parkinson disease.